Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share acquisitions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The only reported activity is the acquisition of GSK Ordinary Shares by specific executives on May 12, 2015, at a price of 1,439.96 pence per share through the ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a routine regulatory disclosure of share purchases.
Important Facts for Investors
- Transaction Date: May 12, 2015.
- Share Price: 1,439.96 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Acquisition Details: Each participant acquired between 8 and 9 shares under both the personal contribution and matching elements of the ShareReward Plan.
- Financial Data: No financial metrics are included in this specific filing.